Marek Broul , Jan Milota , Miroslav Šuráň , Vít Horák , Aneta Hujová , Michaela Liegertová
{"title":"透明细胞肾细胞癌根治性肾切除术后5年晚期皮肤转移至下眼睑1例","authors":"Marek Broul , Jan Milota , Miroslav Šuráň , Vít Horák , Aneta Hujová , Michaela Liegertová","doi":"10.1016/j.eucr.2025.103225","DOIUrl":null,"url":null,"abstract":"<div><div>Clear-cell renal cell carcinoma (ccRCC) metastasises widely, but cutaneous spread is uncommon and eyelid involvement exceptionally rare. We report a 55-year-old man who developed a painless 4-mm lower-eyelid nodule five years after curative left radical nephrectomy for pT1a ccRCC. Excision confirmed metastatic ccRCC (PAX8+, CD10<sup>+</sup>). Staging showed mediastinal nodal and pulmonary disease. First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.</div></div>","PeriodicalId":38188,"journal":{"name":"Urology Case Reports","volume":"63 ","pages":"Article 103225"},"PeriodicalIF":0.4000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Late cutaneous metastasis of clear-cell renal cell carcinoma to the lower eyelid five years after radical nephrectomy: A case report\",\"authors\":\"Marek Broul , Jan Milota , Miroslav Šuráň , Vít Horák , Aneta Hujová , Michaela Liegertová\",\"doi\":\"10.1016/j.eucr.2025.103225\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Clear-cell renal cell carcinoma (ccRCC) metastasises widely, but cutaneous spread is uncommon and eyelid involvement exceptionally rare. We report a 55-year-old man who developed a painless 4-mm lower-eyelid nodule five years after curative left radical nephrectomy for pT1a ccRCC. Excision confirmed metastatic ccRCC (PAX8+, CD10<sup>+</sup>). Staging showed mediastinal nodal and pulmonary disease. First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.</div></div>\",\"PeriodicalId\":38188,\"journal\":{\"name\":\"Urology Case Reports\",\"volume\":\"63 \",\"pages\":\"Article 103225\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214442025002967\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214442025002967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Late cutaneous metastasis of clear-cell renal cell carcinoma to the lower eyelid five years after radical nephrectomy: A case report
Clear-cell renal cell carcinoma (ccRCC) metastasises widely, but cutaneous spread is uncommon and eyelid involvement exceptionally rare. We report a 55-year-old man who developed a painless 4-mm lower-eyelid nodule five years after curative left radical nephrectomy for pT1a ccRCC. Excision confirmed metastatic ccRCC (PAX8+, CD10+). Staging showed mediastinal nodal and pulmonary disease. First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
